Table 4

Adjusted ORs and 95% CIs for congenital musculoskeletal anomalies by tertiles of internal THM exposure during the first trimester of pregnancy

THM internal dose tertile limits (µg/d)nFirst month OR* (95% CI)nSecond month OR* (95% CI)nThird month OR* (95% CI)nFirst trimester OR* (95% CI)
TTHM
 0.031–0.040141141141141
 0.040–0.356140.92 (0.43 to 1.94)140.91 (0.43 to 1.92)150.99 (0.47 to 2.07)130.90 (0.42 to 1.92)
 0.356–2.44890.63 (0.27 to 1.46)90.63 (0.27 to 1.47)80.57 (0.24 to 1.36)100.69 (0.31 to 1.57)
 p†0.3510.3570.2540.446
 Continuous (1 µg/d)0.46 (0.14 to 1.52)0.54 (0.17 to 1.72)0.69 (0.23 to 2.04)0.55 (0.17 to 1.74)
Chloroform
 0.001–0.026161161141171
 0.026–0.288120.71 (0.33 to 1.50)120.69 (0.33 to 1.48)150.98 (0.47 to 2.04)110.61 (0.29 to 1.32)
 0.288–2.10990.56 (0.25 to 1.28)90.56 (0.25 to 1.28)80.57 (0.24 to 1.37)90.51 (0.22 to 1.14)
 p†0.1750.1800.2580.111
 Continuous (1 µg/d)0.37 (0.09 to 1.48)0.43 (0.11 to 1.68)0.55 (0.15 to 2.03)0.43 (0.11 to 1.71)
BDCM
 0.000–0.01311111191101
 0.013–0.051181.57 (0.73 to 3.35)161.41 (0.65 to 3.06)180.88 (0.36 to 2.19)131.18 (0.51 to 2.71)
 0.051–0.43680.73 (0.29 to 1.84)100.92 (0.39 to 2.17)101.70 (0.78 to 3.71)141.29 (0.57 to 2.92)
 p†0.6390.9440.7080.406
 Continuous (0.1 µg/d)0.79 (0.33 to 1.86)0.95 (0.45 to 2.00)1.15 (0.60 to 2.17) 0.97 (0.46 to 2.06)
DBCM
 0.000–0.002716191111
 0.002–0.006111.41 (0.54 to 3.65)132.02 (0.76 to 5.36)90.97 (0.38 to 2.45)120.95 (0.42 to 2.18)
 0.006–0.093192.56 (1.07 to 6.13)182.90 (1.14 to 7.35)192.01 (0.90 to 4.48)141.16 (0.52 to 2.57)
 p†0.0240.0230.0610.578
 Continuous (0.01 µg/d)1.18 (0.86 to 1.62)1.18 (0.90 to 1.56)1.20 (0.94 to 1.54)1.20 (0.91 to 1.58)
  • *Adjusted for: body mass index, fetus number, previous premature birth and infant sex.

  • †χ2 for linear trend.

  • BDCM, bromodichloromethane; DBCM, dibromochloromethane; THM, trihalomethane; TTHM, total trihalomethane.